NASDAQ:PRAH - PRA Health Sciences Stock Price, News, & Analysis

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) announced its quarterly earnings data on Wednesday, October, 31st. The medical research company reported $1.13 EPS for the quarter, beating the Zacks' consensus estimate of $1.07 by $0.06. The medical research company earned $717.60 million during the quarter, compared to analyst estimates of $729.63 million. PRA Health Sciences had a net margin of 2.37% and a return on equity of 25.75%. The firm's revenue for the quarter was up 23.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.88 earnings per share. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences issued an update on its FY18 earnings guidance on Wednesday, October, 31st. The company provided EPS guidance of $4.22-4.27 for the period, compared to the Thomson Reuters consensus estimate of $4.19. The company issued revenue guidance of $2.87-2.92 billion, compared to the consensus revenue estimate of $2.91 billion.PRA Health Sciences also updated its FY 2018 guidance to $4.22-4.27 EPS.

9 equities research analysts have issued 1-year price objectives for PRA Health Sciences' stock. Their forecasts range from $100.00 to $120.00. On average, they expect PRA Health Sciences' share price to reach $112.2222 in the next year. This suggests a possible upside of 9.9% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PRA Health Sciences.

News stories about PRAH stock have trended somewhat positive recently, InfoTrie reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. PRA Health Sciences earned a news sentiment score of 0.6 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.

PRA Health Sciences saw a increase in short interest in October. As of October 31st, there was short interest totalling 1,538,009 shares, an increase of 42.8% from the October 15th total of 1,077,059 shares. Based on an average daily volume of 429,098 shares, the short-interest ratio is currently 3.6 days. Approximately 2.7% of the company's shares are short sold. View PRA Health Sciences' Current Options Chain.

Some companies that are related to PRA Health Sciences include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX) and HedgePath Pharmaceuticals (HPPI).

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.44%), Bank of New York Mellon Corp (3.83%), FMR LLC (3.60%), Eagle Asset Management Inc. (1.67%), Swedbank (1.48%) and Acadian Asset Management LLC (1.45%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., Pictet Asset Management Ltd., Allianz Asset Management GmbH, Tygh Capital Management Inc., Vaughan Nelson Investment Management L.P., Wells Fargo & Company MN, Acadian Asset Management LLC and PNC Financial Services Group Inc.. Company insiders that have sold PRA Health Sciences company stock in the last year include David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was purchased by a variety of institutional investors in the last quarter, including Swedbank, Frontier Capital Management Co. LLC, BlackRock Inc., Laurion Capital Management LP, Bank of New York Mellon Corp, First Trust Advisors LP, Jennison Associates LLC and Artemis Investment Management LLP. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $102.13.

PRA Health Sciences has a market capitalization of $6.65 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.

The official website for PRA Health Sciences is http://www.prahs.com.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]